Фреманезумаб в реальной клинической практике: опыт использования в специализированном центре головной боли

С 2020 г. в России зарегистрированы и успешно применяются анти-CGRP моноклональные антитела (мАТ).

Цель исследования — изучение эффективности и безопасности терапии фреманезумабом (225 мг ежемесячно или 675 мг ежеквартально) в условиях реальной клинической практики у пациентов с мигренью, обратившихся в российский специализированный центр лечения головной боли.

Материал и методы. В открытое ретроспективное исследование вошли 202 пациента (средний возраст — 39,4±12,2 года) с частой эпизодической (ЭМ) или хронической мигренью (ХМ), получивших по меньшей мере три инъекции фреманезумаба 225 мг или три инъекции в суммарной дозе 675 мг и регулярно заполнявшие дневник головной боли «Мигребот» за 1 мес до начала терапии и в течение всего курса лечения.

Результаты. Среднее число дней с мигренью в месяц уменьшилось во всей группе с 20,1±8,2 (до лечения) до 8,5±7,9 через 12 нед (р<0,0001), в группе ЭМ - с 10,9±4,1 До 3,6±3,7 (р<0,0001), в группе ХМ - с 24,4±5,7 до 10,8±8,3 (р<0,0001). Нежелательные явления отмечены у 13 (6,4%) пациентов (наиболее часто — местные реакции: зуд, высыпания, покраснение, уплотнение в месте инъекции).

Заключение. Исследование показало благоприятный профиль эффективности и безопасности фреманезумаба в российской популяции, в которой анти-CGRP мАТ рассматриваются как препараты первой линии для лечения мигрени.

1. Инструкция по медицинскому применению лекарственного препарата Аджови. Доступно по ссылке: https://grls.rosminzdrav.ru_ (дата обращения 27.05.2024).

2. Клинические рекомендации «Мигрень» (взрослые) МЗ РФ, 2021. Доступно по ссылке: https://cr.minzdrav.gov.ru/recomend/295_ (дата обращения 27.05.2024).

3. Dodick DW, Silberstein SD, Bigal ME, et al. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial. JAMA. 2018 May 15;319(19):1999-2008. doi: 10.1001/jama.2018.4853

4. Goadsby PJ, Silberstein SD, Yeung PP, et al. Long-term safety, tolerability, and efficacy of fremanezumab in migraine: A randomized study. Neurology. 2020 Nov 3;95(18):e2487-e2499. doi: 10.1212/WNL.0000000000010600. Epub 2020 Sep 10.

5. Nahas SJ, Naegel S, Cohen JM, et al. Efficacy and safety of fremanezumab in clinical trial participants aged >60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies. J Headache Pain. 2021 Nov 24;22(1):141. doi: 10.1186/s10194-021-01351-2. Erratum in: J Headache Pain. 2022 May 17;23(1):57.

6. Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the Preventive Treatment of Chronic Migraine. N Engl J Med. 2017 Nov 30;377(22):2113-22. doi: 10.1056/NEJMoa1709038

7. Ailani J, Burch RC, Robbins MS; Board of Directors of the American Headache Society. The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache. 2021 Jul;61(7):1021-39. doi: 10.1111/head.14153. Epub 2021 Jun 23.

8. Азимова ЮЭ, Амелин АВ, Алферова ВВ и др. Клинические рекомендации «Мигрень». Журнал неврологии и психиатрии им. С.С. Корсакова. 2022;122(1-3):4-36. doi: 10.17116/jnevro20221220134

9. Diener HC, Forderreuther S, Gaul C, et al. Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor: Addition to the S1 guideline: Therapy of migraine attacks and prevention of migraine. Recommendations of the Germany Society of Neurology and the German Migraine and Headache Society. Neurol Res Pract.2020 Apr 13;2:11. doi: 10.1186/s42466-020-00057-1

10. Sacco S, Amin FM, Ashina M, et al. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention — 2022 update. J Headache Pain. 2022 Jun 11;23(1):67. doi: 10.1186/s10194-022-01431-x

11. Charles AC, Digre KB, Goadsby PJ, et al; American Headache Society. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update. Headache. 2024 Apr;64(4):333-41. doi: 10.1111/head.14692. Epub 2024 Mar 11.

12. Филатова ЕГ, Осипова ВВ, Табеева ГР и др. Диагностика и лечение мигрени: рекомендации российских экспертов. Неврология, нейропсихиатрия, психосоматика. 2020;12(4):4-14. doi: 10.14412/2074-27112020-4-4-14

13. Driessen MT, Cohen JM, Patterson-Lomba O, et al. Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study. J Headache Pain. 2022 Apr 11;23(1):47. doi: 10.1186/s10194-022-01411-1

14. Driessen MT, Cohen JM, Thompson SF, et al. Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine. J Headache Pain. 2022 May 16;23(1):56. doi: 10.1186/s10194-022-01415-x

15. Straube A, Broessner G, Gaul C, et al. Fremanezumab for Preventive Treatment in Migraine: The FINESSE Study (P16-2.001). Neurology. 2022;98(18 Suppl):1678.

16. Ashina M, Mitsikostas DD, Amin FM, et al. Effectiveness of fremanezumab for the preventive treatment of migraine: second interim analysis of the observational PEARL study. Cephalalgia. 2022;42(1S):93-4.

17. Afridi S, Totev TI, Krasenbaum LJ, et al. Real-world reductions in monthly migraine days and migraine-related healthcare resource utilization in UK Patients Using Fremanezumab. Cephalalgia, 2022;42(1S):74-5.

18. Barbanti P, Egeo G, Aurilia C, et al; FRIEND-Study Group. Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study). J Headache Pain. 2022 Apr 9;23(1):46. doi: 10.1186/s10194-022-01396-x. Erratum in: J Headache Pain. 2022 Apr 28;23(1):51. Erratum in: J Headache Pain. 2022 Jun 7;23(1):64.

19. Suzuki K, Suzuki S, Shiina T, et al. Effectiveness of three calcitonin gene-related peptide monoclonal antibodies for migraine: A 12-month, single-center, observational real-world study in Japan. Cephalalgia. 2023 May;43(5):3331024231177649. doi: 10.1177/03331024231177649

20. Argyriou AA, Dermitzakis EV, Xiromerisiou G, et al. Predictors of Response to Fremanezumab in Migraine Patients with at Least Three Previous Preventive Failures: Post Hoc Analysis of a Prospective, Multicenter, Real-World Greek Registry. J Clin Med. 2023 Apr 29;12(9):3218. doi: 10.3390/jcm12093218

21. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018 Jan;38(1):1-211. doi: 10.1177/0333102417738202

22. Skorobogatykh K, Perfilova J, Azimova J. Migrebot — interactive chat-based headache diary. Cephalalgia. 2019;39(1S):44.

23. McAllister P, Lamerato L, Krasenbaum LJ, et al. Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States. J Headache Pain. 2021 Dec 20;22(1):156. doi: 10.1186/s10194-021-01358-9

24. Murray AM, Stern JI, Robertson CE, Chiang CC. Real-World Patient Experience of CGRP-Targeting Therapy for Migraine: a Narrative Review. Curr Pain Headache Rep. 2022 Oct;26(10):783-94. doi: 10.1007/s11916-022-01077-z. Epub 2022 Sep 5.

25. Straube A, Broessner G, Gaul C, et al. Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Study. J Headache Pain. 2023 May 23;24(1):59. doi: 10.1186/s10194-023-01593-2

26. Амелин АВ, Соколов АЮ, Ваганова ЮС. Пятилетний опыт применения нового класса препаратов для таргетной профилактической терапии мигрени. Российский неврологический журнал. 2021;26(3):4-14. doi: 10.30629/2658-7947-2021-26-3-4-14

27. Сергеев АВ, Табеева ГР, Филатова ЕГ и др. Применение новой биологической патогенетической терапии мигрени в клинической практике: консенсус экспертов Российского общества по изучению головной боли. Неврология, нейропсихиатрия, психосоматика. 2022;14(5):109-16. doi: 10.14412/2074-2711-2022-5-109-116

28. Buse DC, Krasenbaum LJ, Seminerio MJ, et al. Real-world Impact of Fremanezumab on Migraine-Related Health Care Resource Utilization in Patients with Comorbidities, Acute Medication Overuse, and/or Unsatisfactory Prior Migraine Preventive Response. Pain Ther. 2024 Jun;13(3):511-32. doi: 10.1007/s40122-024-00583-9. Epub 2024 Mar 12.

29. Takeshima T, Sakai F, Wang X, et al. Cost Effectiveness of Fremanezumab in Episodic and Chronic Migraine Patients from a Japanese Healthcare Perspective. Pharmacoeconomics. 2024 May 21. doi: 10.1007/s40273-024-01380-0. Epub ahead of print.

30. Varnado OJ, Manjelievskaia J, Ye W, et al. Health care resource utilization and costs associated with treatment among patients initiating calcitonin gene-related peptide inhibitors vs other preventive migraine treatments in the United States. J Manag Care Spec Pharm. 2022 Aug;28(8):818-29. doi: 10.18553/jmcp.2022.28.8.818

31. Cantarelli L, Pestana Grafina D, Gonzalez Perez A, et al. Efficacy and Safety of Erenumab, Galcanezumab, and Fremanezumab in the Treatment of DrugResistant Chronic Migraine: Experience in Real Clinical Practice. Ann Pharmacother. 2023 Apr;57(4):416-24. doi: 10.1177/10600280221118402. Epub 2022 Aug 18.

32. Ferrari MD, Zuurbier KWM, Barash S, et al. Fremanezumab in individuals with chronic migraine who had inadequate response to onabotulinumtoxinA and topiramate or valproic acid. Headache. 2022 Apr;62(4):530-3. doi: 10.1111/head.14294. Epub 2022 Apr 6.

33. Krasenbaum LJ, Pedarla VL, Thompson SF, et al. A real-world study of acute and preventive medication use, adherence, and persistence in patients prescribed fremanezumab in the United States. J Headache Pain. 2022 May 4;23(1):54. doi: 10.1186/s10194-022-01413-z

34. Munoz-Vendrell A, Campoy S, Caronna E, et al. Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients. J Headache Pain. 2023 Jun 2;24(1):63. doi: 10.1186/s10194-023-01585-2

35. Gottschalk C, Buse DC, Marmura MJ, et al. The importance of an early onset of migraine prevention: an evidence-based, hypothesis-driven scoping literature review. Ther Adv Neurol Disord. 2022 May 31;15:17562864221095902. doi: 10.1177/17562864221095902

36. Ailani J, Xie H, Driessen M, et al. No ‘Wearing-Off Effect' Seen with Fremanezumab in the Real-World: Retrospective, Claims-Based Analysis of Migraine-Related Healthcare Resource and Acute Medication Use. Neurology. 2023;100(17 Suppl 2):3715. doi: 10.1212/WNL.0000000000203473

37. Blumenfeld AM, Stevanovic DM, Ortega M, et al. No “Wearing-Off Effect” Seen in Quarterly or Monthly Dosing of Fremanezumab: Subanalysis of a Randomized Long-Term Study. Headache. 2020 Nov;60(10):2431-43. doi: 10.1111/head.13994. Epub 2020 Oct 28.

38. Florescu AM, Lannov LV, Younis S, et al. No wearing-off effect of erenumab or fremanezumab for chronic migraine prevention: a single-center, real-world, observational study. Cephalalgia. 2024 Jan;44(1):3331024231222915. doi: 10.1177/03331024231222915